ArticleScientific reports2025
Prevalence and associated factors of hyperuricemia in chronic kidney disease: evidence from a single-center hospital-based study in Ethiopia, 2024.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hypertriglyceridemia in chronic kidney disease: pathophysiological mechanisms, cardiovascular risk, and emerging therapeutics.Lipids in health and disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemia has been implicated in accelerating the progression of chronic kidney disease (CKD). Identifying associated factors may help guide future interventions aimed at delaying CKD progression. To determine the prevalence of hyperuricemia and its associated factors among CKD patients. An institution-based cross-sectional study was conducted among adult CKD patients at the University of Gondar Comprehensive Specialized Hospital from September 2023 to January 2024. A total of 218 patients were enrolled using a consecutive sampling technique. Pretested, structured, interviewer-administered questionnaires were used to collect sociodemographic and clinical data. Data were entered using Epi Data Manager version 4.6 and analyzed with SPSS version 27.0. Multivariate logistic regression analysis was performed to identify factors associated with hyperuricemia, and variables with a p-value of less than 0.05 were considered statistically significant. The mean serum uric acid (SUA) level over the past 3 months was 7.76 mg/dL (SD ± 2.93). Among non-dialysis CKD patients (n = 189), 65.6% (95% CI: 58.7-72.0%) had hyperuricemia. Among all CKD patients (n = 218), the prevalence was 66.1%, and among dialysis patients (n = 29), it was 69.0%. Factors significantly associated with hyperuricemia among non-dialysis CKD patients were: male sex (AOR = 2.01; 95% CI: 1.01-4.28), serum triglyceride > 150 mg/dL (AOR = 4.05; 95% CI: 1.85-8.80), eGFR stage 4 (AOR = 6.31; 95% CI: 2.43-16.40), eGFR stage 5 (AOR = 4.62; 95% CI: 1.59-13.40), BMI 25-29.9 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.